Every kidney study at SCRI in one place: what is enrolling now, what is opening soon, what is under way, and the record behind them. Listings change as protocols open and close.
Study-related visits, tests, and investigational therapy are provided at no cost, and your insurance is never billed. Filter by condition to see what may fit, or open the registry record for the full protocol.
Enrolling nowPraliciguat · Phase 2 · NCT07268638
Praliciguat, an oral sGC stimulator, in adults with primary focal segmental glomerulosclerosis whose protein leak persists on a maximally tolerated ACE inhibitor or ARB.
Who it is forAdults with biopsy-confirmed primary FSGS, a urine protein-to-creatinine ratio of 1 g/g or more on a maximally tolerated ACE inhibitor or ARB, and eGFR of 25 or above.
Enrolling nowAZD2373 · Phase 2 · NCT06824987
AZD2373 in adults with APOL1-mediated kidney disease (AMKD) who carry two high-risk APOL1 variants (G1 and G2), measured by the change in urine albumin at 30 weeks (APPRECIATE).
Who it is forAdults 18 to 70 of African descent with a high-risk APOL1 genotype, a urine albumin-to-creatinine ratio of 300 mg/g or more, and eGFR of 25 or above.
Enrolling nowMuvalaplin · Phase 3 · NCT07157774
Muvalaplin, an oral lipoprotein(a) inhibitor, for reducing heart attack and stroke risk in adults with high Lp(a) who have cardiovascular disease or are at risk of a first event (MOVE-Lp(a)).
Who it is forAdults with Lp(a) of 175 nmol/L or more who have had a cardiovascular event, or are at high risk of one, including reduced kidney function with diabetes.
Two studies are in start-up at SCRI and not yet enrolling. Ask about either now and the study team will keep you in mind for screening.
Opening soonFarabursen · Phase 3
Farabursen, evaluated for slowing total kidney volume growth and the decline in kidney function (eGFR slope) in adults with autosomal dominant polycystic kidney disease.
Opening soonEloralintide · Phase 3
Once-weekly eloralintide for body weight and blood-sugar control in adults with obesity or overweight, type 2 diabetes, and increased cardiovascular risk.
Enrollment has finished in these five studies. Participants already enrolled continue their visits at SCRI, and each study reports its results when it completes.
Closed to enrollmentBAY3283142 · Phase 2 · NCT06522997
BAY3283142 with standard of care for albuminuria in adults with chronic kidney disease (ALPINE 1).
Closed to enrollmentLepodisiran · Phase 3 · NCT06292013
Lepodisiran for cardiovascular risk reduction in adults with high Lp(a) who have cardiovascular disease or are at risk of a heart attack or stroke (ACCLAIM-Lp(a)). Participants are followed through 2029.
Closed to enrollmentRetatrutide · Phase 3 · NCT06383390
Retatrutide's effect on cardiovascular and kidney outcomes in adults living with obesity (TRIUMPH-Outcomes). Participants are followed through 2029.
Closed to enrollmentVeverimer · Phase 3 · NCT07355062
Veverimer for adults with moderate-to-severe chronic kidney disease and metabolic acidosis (REN-012).
Closed to enrollmentBodyport Cardiac Scale · Device study · NCT07059962
Hemodynamic biomarkers from the Bodyport Cardiac Scale, explored for predicting worsening events from fluid overload in people with kidney disease on peritoneal dialysis (SCALE-PD).
Clinical trials often move through SCRI. Here are a few examples.
Tell us a little about your kidney health and the study team will review it against every open protocol, with no cost and no obligation.